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A B S T R A C T
Purpose: We systematically reviewed studies to provide current evidence on the incidence and risk of
skin rash in patients with LTG therapy.
Methods: PubMed and Scopus databases, up to 15 March 2014 were searched to identify relevant
studies. Eligible studies included prospective studies, retrospective studies and postmarketing reports,
which included data of skin rash in patients with LTG therapy.
Results: Forty-one articles met the entry criteria. A total of 4447 patients with LTG therapy from
26 prospective studies, 2977 patients from 8 retrospective studies, and 26,126 patients from 5/7
postmarketing reports were included. The overall incidence of skin rash with LTG therapy was 9.98%
(444/4447) from prospective studies, 7.19% (214/2977) from retrospective studies, and 2.09% (547/
26,126) from postmarketing reports. A meta-analysis of the risk of skin rash in 21 prospective studies,
did not show a signiﬁcant difference between patients with LTG and other drugs, including placebo,
other ADEs or lithium (OR 0.99–2.41). In 6 respective studies, there was a signiﬁcantly higher OR in
patients with LTG compared with those with non-aromatic AEDs. However, there was no signiﬁcant
difference in rash risk between patients with LTG and aromatic AEDs.
Conclusions: Our study showed that LTG signiﬁcantly increased the risk of developing a skin rash
compared to non-aromatic AEDs. Our results support the need for large prospective population-based
studies and clinical trials to determine whether LTG increases the risk of developing a skin rash than
compared to other drugs.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Lamotrigine (LTG) is the most commonly administered second-
line antiepileptic-drugs (ADEs) and is also effective in the treatment
of a variety of other abnormalities of neuronal excitability, including
bipolar disorder [1,2], and neuropathic pain [3]. However, 10% of
subjects in controlled trials are allergic to LTG and are susceptible to
a wide spectrum of adverse cutaneous clinical manifestations
including extremely painful and life-threatening conditions [4].
Skin reactions are a common side effect of antiepileptic drugs
(AEDs) and a major cause of treatment discontinuation. The clinical* Corresponding author. Tel.: +86 01055499218.
** Corresponding author. Tel.: +86 01055499120.
E-mail addresses: bjxqwang@yahoo.com.cn (X.-q. Wang),
lansy@263.net (S.-y. Lang).
http://dx.doi.org/10.1016/j.seizure.2014.12.001
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights respectrum of these reactions is wide. Most skin reactions are
common and mild maculopapular rashes that disappear within a
few days after discontinuing drug use. Benign rashes are relatively
common with aromatic AEDs, such as carbamazepine (CBZ),
phenytoin (PHT), and phenobarbital (PB), with a frequency ranging
from 5 to 15% of treated individuals. Some of the newer drugs also
frequently cause skin rashes, particularly lamotrigine (LTG), and
oxcarbazepine (OXC).
The incidence of rash is now well recognized to be dose- and
titration-dependent, and is related with concomitant therapy with
valproic acid (VPA). Since the introduction of a gradual titration
schedule in 1994, the rate of severe rashes with LTG has declined
from 1 to 0.1–0.01 percent [5]. However, there was not a
substantial reduction observed in the rate of benign rashes, which
has still remained between 8 and 11 percent [6].
Although LTG has been used in everyday clinical practice for
nearly 25 years and the possibility of rash is now routinelyserved.
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risk of developing a skin rash compared to other drugs. Here, we
systematically reviewed published studies to provide current
evidence on the incidence of LTG related skin rashes and compared
this risk with other drugs.
2. Methods
2.1. Search strategy
We searched the PubMed (data from 1990 to March 2014), and
Scopus (up to March 2014) databases for relevant studies. The
search terms used were: ‘‘lamotrigine’’, ‘‘lamictal’’, ‘‘rash’’, and
‘‘skin reaction’’. Studies were limited to human studies and were
published in English.
A cutaneous adverse reaction was deﬁned as any types of rash
(erythematous, maculo-papular, papular, pustular or unspeciﬁed)
that could only be caused by an antiepileptic drug effect and that
resulted in contacting a physician.
2.2. Selection criteria
To determine the practical signiﬁcance of the study, we
evaluated the incidence and the risk of developing a skin rash in
patients who received LTG therapy. Thus, we included multiple
dose levels of LTG treatment. We included all prospective,
retrospective and postmarketing studies reporting a skin rash
with LTG therapy. Clinical trials that met the following criteria
were included in the meta-analysis: (1) prospective randomized
controlled trials or open-label trials of patients receiving LTG
treatment and its presence with a control group; (2) retrospective
study, which included the data of LTG related rashes and could be
compared with other drugs.
We excluded reviews, editorials, single cases and case series,
studies published only as abstracts, letters, or commentaries and
studies they were a part of duplicate populations. For the meta-
analysis, on the basis of the inclusion and exclusion criteria, we
identiﬁed a total of 21 prospective case-controlled studies (1 study
involving Asian subjects and 20 involving European–Caucasian
subjects) (Table 1), and 6 retrospective studies (2 studies involving
Asian subjects and 4 studies involving European–Caucasian
subjects) (Table 2).
2.3. Data extraction and quality assessment
We designed and piloted a standardized data abstraction form
to capture all of the relevant study-level information required for
analysis. Two independent investigators performed the data
extraction (W.X.Q. and X.J.), and any discrepancy between the
reviewers was resolved by consensus. For each study, the following
information was obtained: the author’s name, year of publication,
trial phase, number of enrolled subjects, treatment arms, number
of patients in the treatment and control groups when available,
median age, median treatment duration, and adverse outcomes of
interest (skin rash).
2.4. Statistical analysis
All of the analyses were performed using STATA 12.0
(StataCorp, College Station, Texas, USA). A p-value of less than
0.05 was considered statistically signiﬁcant, and all of the tests
were two-sided. The crude odds ratios (ORs) and 95% conﬁdence
intervals (CIs) were used to express the risk of skin rash with LTG
therapy compared with other drugs. Forest plots were used to
depict the visual representation of the meta-analysis results. Meta-
analysis was performed using ﬁxed-effects [7] or random-effects[8] models. Heterogeneity was tested using w2-based Cochran’s Q
statistic [9] and I2 metric statistics [10]. Random-effects models
were used only when there was considerable heterogeneity
(P < 0.05 or I2 > 50% among the studies).
Studies were classiﬁed according to the study type (prospective
study, retrospective study and postmarketing reports). In the ﬁrst
two group, all of the crude OR calculated by the original data were
pooled. We performed the analyses on only the observed crude
rate estimates, primarily because there was no study that reported
adjusted estimates. We also performed the following speciﬁed
subgroup analyses: different control groups (placebo, other
antiepileptic drugs, or other antidepressive drugs), different
groups of patients (epilepsy, bipolar or patients with neuropathic
pain), prospective study, and retrospective study.
3. Results
3.1. Study selection and characteristics
Our search yielded 748 records describing the use of LTG and a
skin rash from the Pubmed and Scopus databases. The selection
process is summarized in Fig.1. After the exclusion of duplicate
studies and a review of the abstracts, a total of 94 human clinical
studies were identiﬁed with information on LTG therapy and
benign rashes. Full-text articles were retrieved for these records
and carefully studied. Finally, in the prospective studies, a total of
26 studies involving LTG-induced rash were used to evaluate rash
incidence [11–36] and 21 articles with controls fulﬁlling the
inclusion and exclusion criteria were identiﬁed for meta-analysis
[11–31] (Fig.1 and Table 1). In this group, 4447 patients receiving
LTG treatment were investigated, including a variety of diseases:
epilepsy (13 trials) [15,16,23–30,33,34,36], dipolar disorder (9
trials) [17–22,31,32,35], and neuropathic pain (1 magraine [11], 1
multiple sclerosis [12], 1 HIV-related [13], and 1 diabetic [14]). The
sample sizes were within the range of 20–958 patients with LTG.
The median age of study participants was 9.6–77 years.
In the retrospective studies, 8 articles were used to evaluate
rash incidence [37–44] and 6 studies fulﬁlling the inclusion criteria
were identiﬁed for meta-analysis [37–42], which were all derived
from epileptic studies (Fig.1 and Table 2). The sample sizes were
within the range of 8–1037 patients treated with LTG. Two articles
were pediatric studies, of which one study included all age groups
and 5 studies included patients older than 12 years.
There were 5/7 postmarketing studies that provided data on the
skin rash incidence of LTG [45–47,49,50] (Table 3). Four studies
were performed in the U.K., which were performed by Prescrip-
tion-Event Monitoring (PEM) to establish the safety of LTG and
other drugs, in which the entire population of prescriptions issued
was accessible [45–47,50]. One study was performed in Germany
[49], where the data were obtained from a database of 208,401
psychiatric inpatients who were monitored by the Safety surveil-
lance project Drug Safety in Psychiatry from 1993 to 2005, which
surveys clinically relevant adverse reactions to all marketed
psychotropic drugs. One report was performed in Sweden [51],
which aimed to determine the extent of the spontaneous reporting
of ADRs in children. One study was on the safety proﬁle of
antiepileptic drugs in Italy [48], from January 1988 to June 2005.
Only 2/7 of these studies followed cohorts of more than 10,000
subjects [45,49].
3.2. Incidence of skin rash
The overall incidence of skin rash with LTG treatment was 9.98%
(444/4447) from 26 prospective clinical trials, 7.19% (214/2977)
from 8 retrospective studies, and 2.09% (547/26,126) from 5
postmarketing reports.
Table 1
Characteristics of published prospective studies reporting skin rash with LTG therapy.
Study Country Study ﬁeld Study
type
Age
group
No.
enrolled
Treatment
arm
Median
age (y)
M/F
(N/N)
Median
treatment
LTG
dosage
No.
analysis
No.
rash
No.
withdrawal
Steiner et al. (1997) [11] U.K. Pain migraine RCTs Adults 110 LTG 35.8 6/31 3M 200mg/d 37 11 8
LTG ﬁxed dose 200mg/d 18 7 7
LTG escalated dose 200mg/d 19 4 1
Placebo 38.4 8/32 3M 40 1 1
Kapoor et al. (2010) [12] Ireland Pain MS RCTs Adults 120 LTG 51.9 16/45 48M 400mg/d 61 12 3
Adults Placebo 50.1 27/42 48M 59 3 2
Simpson et al. (2003) [13] USA Pain HIV RCTs Adults 220 LTG 46 137/13 11w 402mg/d 150 21 2
Placebo 44 60/17 11w 77 9 1
Vinik et al. (2007) [14] USA Pain DM RCTs Adults 360 LTG 200 60.3 50/38 19w 200mg/d 88 9
LTG 300 60.0 50/40 19w 300mg/d 90 10
LTG 400 59.6 51/38 19w 400mg/d 89 14
1 Placebo 59.8 66/22 19w 88 8
Messenheimer et al. (1994) [15] USA Epi RCTs cross
over
98 LTG 35 41/47 14w 400mg/d 94 14 3
Placebo 35 41/47 14w 96 6 1
Motte et al. (1997) [16] USA Epi RCTs 3-25y 169 LTG 9.6 54/25 16w 50–400mg/d 79 7
Placebo 10.9 45/45 16w 90 6
van der loos et al. (2010) [17] Nertherland Bipolar RCTs Adults 124 LTG 45.2 27/37 16w 64 9
Placebo 47.6 30/30 16w 60 4
Calabrese et al. (1999) [18] Lamictal study
602 Group
Bipolar RCTs Adults 194 LTG 50mg/d 41 22/44 7w 50mg/d 66 9
LTG 200mg/d 42 28/35 7w 200mg/d 63 7
Placebo 42 27/38 7w 65 7
Calabrese et al. (2003) [19] Lamictal 605
study group
Bipolar Open-label Adults 966 LTG 42.4 370/586 16w 200mg/d 958 104
RCTs LTG 44.1 70/89 18M 50–200mg/d 169 12
Lithium 43.6 48/73 18M 121 5
Placebo 42.1 61/60 18M 121 3
Normannet al. (2002) [20] Germany Bipolar RCTs Adults 40 LTG 39.6 6/14 9w 200mg/d 20 3
Placebo 37.9 7/13 9w 20 1
Bowden et al. (2003) [21] Lamictal 606
study group
Bipolar Open-label Adults 349 LTG 40.7 172/175 8–16w 347 38 17
RCTs Adults 174 LTG 40.6 26/33 18M 59 2 0
Lithium 41.9 22/24 18M 46 4 2
Placebo 40.9 34/35 18M 69 6 2
Sajatovic et al. (2005) [22] USA Bipolar RCTs Elderly 98 LTG 60.5 16/17 18M 223mg/d 33 1
Lithium 60.1 13/21 18M 740.7mg/d 34 2
Placebo 62.2 17/14 18M 31 1
Reunanen et al. (1996) [23] U.K. Epi RCTs 12–72 343 LTG 100 33 54/61 24w 100mg/d 115 6 2
LTG 200 30 58/53 24w 200mg/d 111 9 3
CBZ600 32 50/67 24w 600mg/d 117 10 6
Brodie et al. (1995) [24] U.K. Epi RCTs 13–81 260 LTG 28 54/77 12w 150mg/d 131 25 12
CBZ 27 58/71 12w 600mg/d 129 25 17
Brodie et al. (1999) [25] U.K. Epi RCTs Elderly 150 LTG 77 55/47 24w 57–500mg/d 102 9 3
CBZ 76 28/20 24w 200–2000mg/d 48 25 9
ZengK et al. (2010) [26] China Epi open trial Adults 512 LTG 31 34/52 24M 86 4 4
CBZ 27 87/81 24M 168 2 2
PHT 30 36/23 24M 59 1 1
VPA 28 104/88 24M 192 0 0
Gilliam et al. (1998) [27] U.K. Epi RCTs Adults 156 LTG add on 37 33/43 8w 500mgd 76 8
VPA add on 36 32/48 8w 1000mg/d 80 6
LTG alone 37 33/43 12w 500mgd 76 1
VPA alone 36 32/48 12w 1000mg/d 80 1
Steiner et al. (1999) [28] U.K. Epi RCTs 13–70 181 LTG 28 47/39 6–48w 150mg/d 86 12
PHT 27 54/41 6–48w 300mg.d 95 9
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Labiner et al. (2009) [29] USA Epi RCTs Adults 268 LTG 38.3 63/69 12w 400mg/d 132 8
LEV 39.1 56/80 12w 2000mg/d 136 9
Kluger et al. (2001) [30] Germany Epi Open-label Children 95 LTG 13.6 21/18 5y 39 5 2
VGB 11.1 30/26F 56 1
Licht et al. (2010) [31] Sweden Bipolar RCTs Adults 155 LTG 38.2 37/40 5y 400mg/d 77 6
Lithium 37.3 42/36 78 5
Brawn et al. (2006) [32] USA Bipolar RCTs 410 LTG 37.2 77/128 7w 205 14
OFX 36.8 87/118 205 6
Brodie et al. (1997) [33] U.K. Epi RCTs 14–77 347 With VPA 28 48/69 16w 96mg/d 117 20
With CBZ 31 61/68 16w 347mg/d 129 9
With PHT 33 45/50 16w 359mg/d 95 0
Farrell et al. (1996) [34] Canada Epi Open-label Children 56 With VPA 24M 21 4
Without VPA 24M 35 1
Calabrease et al. (1999) [35] USA Bipolar Open-label Adults 75 With VPA 48W 15 1
LTG alone 48W 60 6
Beghi et al. (2003) [36] U.K. Epi Open-label All age 360 LTG alone 12M 158 7
LTG add on 111 5
Epi: epilepsy; MS: multiple sclerosis; HIV: HIV related neuropathic pain; DM: diabetic neuropathic pain; RCTs: randomized controlled trials; LTG: lamotrigine; VPA: valproic acid; PHT:phenytoin; CBZ: carbamazepine; PB:
phenobarbital; LEV: leveritacetam; VGB: vigabatrin; OFX: olanzapine/ﬂuoxetine combination.
Table 2
Characteristics of published retrospective studies reporting skin rash with LTG therapy.
Study Country Study
ﬁeld
Age group Median treatment (weeks) Patients
enrolled
Treatment arm No of
analysis
No of skin
rash
Wang et al. (2012) [37] China Epi Adults (18y) February 1999–April 2010 3793 LTG 261 23
CBZ 58/1919; VPA 8/1754; OXC 15/214; TPM 7/667;
GBP 1/52; LEV 2/121
Chung et al. (2007) [38] USA Epi Adults (17–89y) 104weeks 828 LTG 251 18
OXC 6/97; TPM 6/156; LEV 1/196; ZNS 4/128
Arif et al. (2007) [39] USA Epi >16y January 2000–January 2005 5025 LTG 1037 50
CBZ 24/655; PHT 32/558; OXC 6/248; ZNS 10/219;
GBP 1/378; VPA 3/411; LEV 4/627
Hirsch et al. (2008) [40] USA Epi 12y January 2000–January 2005 1875 LTG 864 77
CBZ 62/745; OXC 10/201; PHT 85/716; PB 17/276; ZNS 12/174
Alvestad et al. (2007) [41] Norway Epi Adults No data 2567
exposures
LTG 359 29
CBZ 54/489; PHT 19/229; OXC 9/114; PB 4/211; VPA 1/391;
LEV 1/155; TPM 0/141; VGB 0/144; GBP 0/73
Mogami et al. (2012) [42] Japan Epi All age February 1996–May 2009 76 LTG 8 2
CBZ 6/55; VPA 2/57; PB 5/35; PHT 4/32; GBP 0/13
Shechter et al. [43] Israel Epi Children 6–14w 110 LTG 65 4
TPM 0/45
McDonald et al. (2004) [44] Ireland Epi Children February 1996–September 2000 251 LTG 132 11
VGB 0/129; GBP 0/39
Epi: epilepsy; LTG: lamotrigine; VPA: valproic acid; PHT: phenytoin; CBZ: carbamazepine; PB: phenobarbital; OXC: oxcarbazepine; GBP: gabapentin; TPM: topiramate; LEV: leveritacetam; VGB: vigabatrin; ZNS: zonisamide.
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Fig. 1. Flow chart of selection of articles about skin rash in patients with LTG therapy.
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3.3.1. Meta-analysis from prospective studies
To investigate the speciﬁc contribution of LTG in the develop-
ment of a skin rash, we independently evaluated the OR of LTG-
associated skin rashes compared with placebo control, lithium, and
other AEDs. Our results showed that the use of LTG did not
signiﬁcantly increase the risk of developing a skin rash over
placebo [in neuropathic pain group (4 studies): OR 2.41, 95% CI:
0.99–5.91; in epilepsy group (2 studies): OR 1.99, 95% CI: 0.95–
4.81; and in bipolar group (6 studies): OR 1.49, 95% CI: 0.87–2.56],
lithium (5 articles: OR 1.12, 95% CI: 0.62–2.03), other aromatic
AEDs (5 articles: OR 0.99, 95% CI: 0.53–1.84), or non-aromatic AEDs
(3 articles: OR 1.44, 95% CI: 0.75–2.76) (Fig.2). We did not perform
a sensitivity analysis, and we studied the published bias to
examine the stability and reliability of pooled OR of LTG-related
skin rashes by the sequential omission of individual studies due to
the small number of studies in each group.
3.3.2. Meta-analysis from retrospective studies
All 6 retrospective studies were epileptic studies. There was a
signiﬁcantly higher OR in patients with LTG treatment compared
with non-aromatic AEDs [VPA (4 studies): OR 13.21, 95% CI 6.71–
26.01; TPM (3 studies): OR 4.16, 95% CI 1.82–9.47; GBP (2 studies):
OR 11.71, 95% CI 2.88–47.58; LEV (4 studies): OR: 8.87, 95% CI 4.32–
18.23], except ZNS [(3 studies): OR 1.35, 95% CI 0.88–2.08](Fig.3).There was no signiﬁcant difference in the rash risk between
patients with LTG and aromatic AEDs [CBZ (6 studies): OR 1.41, 95%
CI 0.93–2.15; OXC (5 studies): OR 1.38, 95% CI 0.99–1.92; and PHT
(4 studies): OR 0.80, 95% CI 0.63–1.02], except PB [(3 studies): OR
1.99, 95% CI 1.25–3.17] (Fig.4). Due to the small number of studies in
each group, we did not perform a sensitivity analysis, and we studies
the published bias to examine the stability and reliability of pooled
OR of LTG-related skin rash.
Furthermore, in prospective studies, we observed a low
heterogeneity when studying LTG with placebo in epileptic
patients, with placebo or lithium in bipolar patients, and with
non-aromatic AEDs (I2 = 0%, 7.4%, 0%, 8.3%, respectively). However,
a considerable heterogeneity of more than 50% was observed in
cases of placebo in patients with neuropathic pain and aromatic
AEDs (I2 = 59.9%, 54.7%, respectively).
In retrospective studies, we observed a low heterogeneity when
studying the LTG with OXC, PHT, VPA, GBP, LEV, and ZNS (I2 = 0%,
0%, 0%, 5%, 0%, 0%, respectively). However, a considerable
heterogeneity of more than 50% was observed in cases of CBZ,
TPM (I2 = 69.8%, 65.2%, respectively).
4. Discussion
Our estimates showed that the overall incidence of skin rash
with LTG therapy was 9.98% from prospective studies, 7.19% from
retrospective studies, and 2.09% from postmarketing reports. The
Table 3
Characteristics of published postmarketing studies reporting skin rash with LTG therapy.
Study Country Age
group
A group rash (n) A group
no rash (n)
B group
rash (n)
B group
no rash (n)
A/B Remark
Mackay et al.
(1997) [45]
U.K. C 47 1551 212 10,529 LTG 2–12 y/
LTG total
cohort
ID per 1000 patient-months in
the ﬁrst month of treatment
Wong et al.
(2001) [46]
U.K. All age
(7–77 y)
100 950 8 353 LTG/GBP Event frequency during ﬁrst six
months after starting the drug
100 950 12 701 LTG/VGB
Acharya et al.
(2005) [47]
U.K. D 204 10,690 12 2971 LTG/GBP Adverse events causing
treatment failure
Iorio et al.
(2007) [48]
Italy All age LTG 34/51 (67%); CBZ 124/208 (60%);
PB 68/98 (69%); GBP 20/80 (25%);
PHT 30/56 (54%); VPA 14/55 (25%);
OXC 11/43 (26%); VGB 0/35 (0%)
Rash Skin reactions/number
of reports total
SJS: PB 10; CBZ 13; PHT 7; LTG 4 SJS Serious skin reactions
TEN: PB 7; CBZ 1; PHT 1; LTG 1 TEN
Lange-Asschenfeldt
et al. (2009) [49]
Germany All age 17 2731 60 18,706 LTG/CBZ Cutaneous adverse reactions to
psychotropic drugs
17 2731 3 1409 LTG/OXC
17 2731 9 14,617 LTG/VPA
Aurich-Barrera
et al. (2010) [50]
U.K. Children 48 2409 131 7248 LTG rash:
children/
adults
Reasons for stopping
5 2452 4 7373 LTG SJS:
children/
adults
Wallerstedt
et al. (2011) [51]
Sweden Children 3 1654 Serious individual case safety
reports (ICSRs)
C: mean age: male 29 y, female 30 y; D: mean age: 30.5 y; LTG: lamotrigine; VPA: valproic acid; CBZ: carbamazepine; OXC: oxcarbazepine; GBP: gabapentin; VGB: vigabatrin;
ID: incidence density; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis.
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prospective data for 3348 patients from placebo-controlled and
open trials of LTG in adults, which showed that 10% of patients
exposed to LTG developed a rash [52,53].
This incidence is lower in retrospective studies compared to
prospective studies, which indicates a limitation in this type of
study. A retrospective study usually underestimates the true
incidence due to recall bias or a physician bias when determining
whether a speciﬁc rash is related to a given medication.
The postmarketing studies use relatively different methods
from prospective trials or retrospective studies, which were
performed by a spontaneous report or Prescription-Event Moni-
toring (PEM) to establish the safety of LTG and other drugs. There
were four studies performed in the U.K., one study performed in
Germany, one study performed in Italy, and one study performed
in Sweden. The Drug Safety Research Unit (DSRU) performed
PEM [54,55] of newly marketed drugs with widespread use in
general practice in England, particularly with drugs that are
intended for long-term use. However, systematic postmarketing
surveillance of AEDs is still generally lacking, and large-scale
postmarketing surveillance was performed to assess the safety of
LTG in U.K. [45–47,50].
The main weakness of comparative PEM analysis is the potential
for bias to confound differences between drugs [54,55]. Under-
reporting is a main disadvantage because the absolute number of
ADR reports is not truly known. Data obtained from spontaneous
reports or PEM when taken alone do not accurately quantify the risk
associated with a drug. The reporting rate may vary over time and be
inﬂuenced by factors, such as media attention. Although such
studies cannot eliminate bias as effectively as RCTs, their strength
lies where the RCT is often weakest, in providing a large number of
patients from whom relative discontinuation rates can be precisely
estimated.
In this meta-analysis of 21 prospective studies, we did not ﬁnd
a signiﬁcant difference between patients with LTG and other
drugs, including placebo, other ADEs and lithium (OR 0.99–2.41).In 6 respective studies, there was a signiﬁcantly higher OR in
patients with LTG compared with non-aromatic AEDs, which
indicated that LTG treatment might signiﬁcantly increase the risk
of developing skin rash compared to non-aromatic AEDs.
There was no signiﬁcant different in rash risk between patients
with LTG and aromatic AEDs, except PB. Due to few prospective
control studies, we did not determine whether this merely
reﬂected a publication bias or whether the risk of skin rash with
LTG therapy is truly not higher compared to other aromatic AEDs
or placebo.
Epilepsy is a serious chronic brain disorder that is characterized
by recurrent unprovoked seizures that can be successfully treated
and controlled using mono- or polytherapy in most patients. Skin
reactions are a common side effect of AEDs and a major cause of
treatment discontinuation [56]. Benign rash is relatively common
with aromatic AEDs, such as CBZ, PHT and PB, with a frequency
ranging from 5% to 15% of treated individuals. In addition, several
newer drugs also frequently cause skin rashes, particularly LTG and
OXC. Wang et al. [57] reported that skin reactions were three times
more frequent with aromatic AEDs compared to non-aromatic
AEDs.
5. Reliability of the study
There are several limitations to this study. First, the number of
studies that addressed skin rashes with LTG therapy is small, in
which only 4447 patients with LTG treatment from 26 prospective
studies and 2977 patients from 8 retrospective studies were
included in this study. A few studies have reported serious life-
threatening rashes; however, we could not obtain the incidence
of a serious rash. Second, different study designs, treatment
strategies, durations and concomitant administration of drugs
contribute to an increase in the clinical heterogeneity of the meta-
analysis, which make the interpretation of the meta-analysis more
problematic. Third, the data did not allow us to perform
multivariable regression to determine which variables were
Fig. 2. The prospective studies about OR of LTG-skin rash compared with other drugs.
X.- Wang et al. / Seizure 25 (2015) 52–6158
Fig. 3. The retrospective studies about OR of LTG-skin rash compared with non-aromatic AEDs.
X.- Wang et al. / Seizure 25 (2015) 52–61 59independently related with LTG-induced skin rash, including the
LTG titration speed and cotreatment with VPA. Forth, it was not
possible to use narrower age categories because the studies
provided either overall estimates or age-speciﬁc estimates withdifferent age categories. Finally, we could not perform a publica-
tion bias test in our review because the meta-analyses in each
group were less than 10 studies, which are considered the baseline
number for testing publication bias.
Fig. 4. The retrospective studies about OR of LTG-skin compared with aromatic AEDs.
X.- Wang et al. / Seizure 25 (2015) 52–6160Nevertheless, despite these limitations, our study provides a
platform for vast heterogeneous data in studies exploring the risk
of LTG-induced skin rash under a common roof and provides some
important insights.
6. Conclusion
On the basis of the ﬁndings of the present study and the existing
literature, the overall incidence of skin rash with LTG therapy was
9.98% from prospective studies, 7.19% from retrospective studies,
and 2.09% from postmarketing reports. These data could poten-
tially be used to assess the burden and analyze the risk of
developing a skin rash in patients with LTG therapy. Our results
showed that LTG signiﬁcantly increased the risk of developing a
skin rash compared to non-aromatic AEDs. Taken together, these
results support the need for large prospective population-based
studies and clinical trials to conﬁrm whether LTG increases the risk
of developing a skin rash compared to other drugs.
Conﬂicts of interest statement
None declared.Acknowledgments
This work was supported by a National Natural Science
Foundation grant funded by the Chinese government. (No.
81271438) We also thank Prof. Gilter (Department of Genetics,
Stanford University School of Medicine) for inviting Dr. Wang as a
visiting scholar of Stanford University and for providing access to
published papers.
References
[1] Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin
Psychiatry 2013;74(7):675–84.
[2] Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing
for pregnant patients with bipolar disorder. Am J Psychiatry 2013;170(11):
1240–7.
[3] Brix Finnerup N, Hein Sindrup S, Staehelin Jensen T. Management of painful
neuropathies. Handb Clin Neurol 2013;115:279–90.
[4] Yarbrough 3rd DR. Experience with toxic epidermal necrolysis treated in a
burn center. J Burn Care Rehabil 1996;17(1):30–3.
[5] Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-
Johnson syndrome and toxic epidermal necrolysis in new users of antiepilep-
tics. Neurology 2005;64(7):1134–8.
[6] Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, et al.
Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance
and management. J Clin Psychiatry 2002;63(11):1012–9.
X.- Wang et al. / Seizure 25 (2015) 52–61 61[7] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retro-
spective studies of disease. J Natl Cancer Inst 1959;22(4):719–48.
[8] DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical
trials: an update. Contemp Clin Trials 2007;28(2):105–14.
[9] Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome
searches. Genet Epidemiol 2005;28(2):123–37.
[10] Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews.
Ann Intern Med 1997;127(9):820–6.
[11] Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis
of migraine with and without aura. Cephalalgia 1997;17(2):109–12.
[12] Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamo-
trigine for neuroprotection in secondary progressive multiple sclerosis: a
randomized, double-blind, placebo-controlled, parallel-group trial. Lancet
Neurol 2010;9(7):681–8.
[13] Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, et al. Lamotrigine
for HIV-associated painful sensory neuropathies: a placebo-controlled trial.
Neurology 2003;60(9):1508–14.
[14] Vinik AI, Tuchman M, Saﬁrstein B, Corder C, Kirby L, Wilks K, et al. Lamotrigine
for treatment of pain associated with diabetic neuropathy: results of two
randomized, double-blind, placebo-controlled studies. Pain 2007;128(1–2):
169–79.
[15] Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R,
et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-con-
trolled, double-blind, cross-over trial. Epilepsia 1994;35(1):113–21.
[16] Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P.
Lamotrigine for generalized seizures associated with the Lennox-Gastaut
syndrome. N Engl J Med 1997;337(25):1807–12.
[17] van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden
MS, et al. Efﬁcacy and safety of two treatment algorithms in bipolar depres-
sion consisting of a combination of lithium, lamotrigine or placebo and
paroxetine. Acta Psychiatr Scand 2010;122(3):246–54.
[18] Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-
blind placebo-controlled study of lamotrigine monotherapy in outpatients
with bipolar I depression. J Clin Psychiatry 1999;60(2):79–88.
[19] Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A
placebo-controlled 18-month trial of lamotrigine and lithium maintenance
treatment in recently depressed patients with bipolar I disorder. J Clin Psychi-
atry 2003;64(9):1013–24.
[20] Normann C, Hummel B, Scha¨rer LO, Ho¨rn M, Grunze H, Walden J. Lamotrigine
as adjunct to paroxetine in acute depression: a placebo-controlled, double-
blind study. J Clin Psychiatry 2002;63(4):337–44.
[21] Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A
placebo-controlled 18-month trial of lamotrigine and lithium maintenance
treatment in recently manic or hypomanic patients with bipolar I disorder.
Arch Gen Psychiatry 2003;60(4):392–400.
[22] Sajatovic M, Gyulai L, Calabrese JR, Thompson TR, Wilson BG, White R, et al.
Maintenance treatment outcomes in older patients with bipolar I disorder. Am
J Geriatr Psychiatry 2005;13(4):305–11.
[23] Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative
trial of lamotrigine and carbamazepine as monotherapy in patients with
newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23(2):149–55.
[24] Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and
carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine
Monotherapy Trial Group. Lancet 1995;345(8948):476–9.
[25] Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised
comparison between lamotrigine and carbamazepine in elderly patients with
newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy
Res 1999;37(1):81–7.
[26] Zeng K, Wang X, Xi Z, Yan Y. Adverse effects of carbamazepine, phenytoin,
valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
Clin Neurol Neurosurg 2010;112(4):291–5.
[27] Gilliam F, Vazquez B, Sackellares JC, Chang GY, Messenheimer J, Nyberg J, et al.
An active-control trial of lamotrigine monotherapy for partial seizures. Neu-
rology 1998;51(4):1018–25.
[28] Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, et al.
Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-
blind comparison with phenytoin. Epilepsia 1999;40(5):601–7.
[29] Labiner DM, Ettinger AB, Fakhoury TA, Chung SS, Shneker B, Tatum Iv WO,
et al. Effects of lamotrigine compared with levetiracetam on anger, hostility,
and total mood in patients with partial epilepsy. Epilepsia 2009;50(5):434–42.
[30] Kluger G, Berz K, Holthausen H. The long-term use of vigabatrin and lamo-
trigine in patients with severe childhood onset epilepsy. Eur J Paediatr Neurol
2001;5(1):37–40.
[31] Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus
lithium as maintenance treatment in bipolar I disorder: an open, randomized
effectiveness study mimicking clinical practice. The 6th trial of the DanishUniversity Antidepressant Group (DUAG-6). Bipolar Disord 2010;12(5):
483–93.
[32] Brown EB, McElroy SL, Keck Jr PE, Deldar A, Adams DH, Tohen M, et al. A
7-week, randomized, double-blind trial of olanzapine/ﬂuoxetine combination
versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry
2006;67(7):1025–33.
[33] Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism
with sodium valproate? 105 Study Group. Epilepsy Res 1997;26(3):423–32.
[34] Farrell K, Connolly MB, Munn R, Peng S, MacWilliam LM. Prospective, open-
label, add-on study of lamotrigine in 56 children with intractable generalized
epilepsy. Pediatr Neurol 1997;16(3):201–5.
[35] Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck Jr PE, et al.
Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder.
Am J Psychiatry 1999;156(7):1019–23.
[36] Beghi E, Gatti G, Tonini C, Ben-Menachem E, Chadwick DW, Nikanorova M,
et al. Adjunctive therapy versus alternative monotherapy in patients with
partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic
controlled trial. Epilepsy Res 2003;57(1):1–13.
[37] Wang XQ, Lang SY, Shi XB, Tian HJ, Wang RF, Yang F. Antiepileptic drug-
induced skin reactions: a retrospective study and analysis in 3793 Chinese
patients with epilepsy. Clin Neurol Neurosurg 2012;114(7):862–5.
[38] Chung S, Wang N, Hank N. Comparative retention rates and long-term tolera-
bility of new antiepileptic drugs. Seizure 2007;16(4):296–304.
[39] Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW,
et al. Comparison and predictors of rash associated with 15 antiepileptic
drugs. Neurology 2007;68(20):1701–9.
[40] Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor Jr SR, Bazil CW. Cross-sensitivity
of skin rashes with antiepileptic drug use. Neurology 2008;71(19):1527–34.
[41] Alvestad S, Lydersen S, Brodtkorb E. Inﬂuence by gender, age, and learning
disability. Epilepsia 2007;48(7):1360–5.
[42] Mogami Y, Takahashi Y, Takayama R, Ohtani H, Ikeda H, Imai K, et al.
Cutaneous adverse drug reaction in patients with epilepsy after acute en-
cephalitis. Brain Dev 2012;34(6):496–503.
[43] Shechter T, Shorer Z, Kramer U, Lerman-Sagie T, Ronen E, Rotem R, et al.
Adverse reactions of topiramate and lamotrigine in children. Pharmacoepide-
miol Drug Saf 2005;14(3):187–92.
[44] McDonald DG, Najam Y, Keegan MB, Whooley M, Madden D, McMenamin JB.
The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in
intractable epilepsy of childhood. Seizure 2005;14(2):112–6.
[45] Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long-term
lamotrigine in epilepsy. Epilepsia 1997;38(8):881–6.
[46] Wong IC, Mawer GE, Sander JW. Adverse event monitoring in lamotrigine
patients: a pharmacoepidemiologic study in the United Kingdom. Epilepsia
2001;42:237–44.
[47] Acharya NV, Pickering RM, Wilton LW, Shakir SA. The safety and effectiveness
of newer antiepileptics: a comparative postmarketing cohort study. J Clin
Pharmacol 2005;45(4):385–93.
[48] Iorio ML, Moretti U, Colcera S, Magro L, Meneghelli I, Motola D, et al. Use and
safety proﬁle of antiepileptic drugs in Italy. Eur J Clin Pharmacol 2007;63(4):
409–15.
[49] Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel RR, Ru¨ther E,
Cordes J. Cutaneous adverse reactions to psychotropic drugs: data from a
multicenter surveillance program. J Clin Psychiatry 2009;70(9):1258–65.
[50] Aurich-Barrera B, Wilton L, Brown D, Shakir S. Paediatric postmarketing
pharmacovigilance using prescription-event monitoring: comparison of the
adverse event proﬁles of lamotrigine prescribed to children and adults in
England. Drug Saf 2010;33(9):751–63.
[51] Wallerstedt SM, Brunlo¨f G, Sundstro¨m A. Rates of spontaneous reports of
adverse drug reactions for drugs reported in children: a cross-sectional study
with data from the Swedish adverse drug reaction database and the Swedish
Prescribed Drug Register. Drug Saf 2011;34(8):669–82.
[52] Manasco P, Mullens L, Matsuo F. Skin rash associated with Lamictal: incidence,
time to onset and risk factors. Epilepsia 1996;37(Suppl. 5):S164.
[53] Guberman AH. Lamotrigine-associated rash risk/beneﬁt considerations in
adults and children. Epilepsia 1999;40(4):985–91.
[54] Mann RD. Prescription-event monitoring recent progress and future horizons.
Br J Clin Pharmacol 1998;46(3):195–201.
[55] Layton D, Pearce GL, Shakir SAW. Safety proﬁle of tolterodine as used in
general practice in England: results of prescription-event monitoring. Drug Saf
2001;24(9):703–13.
[56] Aouam K, BelHadj Ali H, Youssef M, Chaabane A, Amri M, Boughattas NA, et al.
Carbamazepine-induced DRESS and HHV6 primary infection: the importance
of skin tests. Epilepsia 2008;49(9):1630–3.
[57] Wang XQ, Shi XB, Au R, Chen FS, Wang F, Lang SY. Inﬂuence of chemical
structure on skin reactions induced by antiepileptic drugs – the role of the
aromatic ring. Epilepsy Res 2011;94(3):213–7.
